I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ESMO IO 2022

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Dec 8 / Roche and Genentech
IMscin001 (Part 2: Randomized Phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC)
IMscin001 Part 2 is an open-label, randomized, multicenter, Phase Ib/III study (NCT03735121) to investigate non-inferiority of drug exposure at Cycle 1 atezolizumab subcutaneous vs intravenous in patients with second line non-small-cell lung cancer.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 8 / Roche and Genentech
IMpower010: exploratory overall survival with adjuvant atezolizumab vs best supportive care in stage II-IIIA NSCLC ?with high PD-L1 expression
IMpower010 (NCT02486718) is a randomized, open-label, phase III study of adjuvant atezolizumab compared with best supportive care in patients with completely resected stage IB-IIIA NSCLC who received adjuvant cisplatin-based chemotherapy. This poster reports the overall survival data for patients with stage II-IIIA PD-L1 TC ≥50% NSCLC.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 8 / Roche and Genentech
Effectiveness and Safety Data From IMreal Cohort 1: Patients With UrothelialCancer (UC) Receiving Atezolizumab After Platinum-Containing Chemotherapy Under Real-World Conditions.
IMreal is a prospective, non-interventional, multi-centre, multi-cohort study of atezolizumab in patients with advanced/metastatic urothelial cancer in real-world, routine clinical practice. This poster reports effectiveness and safety for Cohort 1 patients who received atezolizumab after platinum-containing chemotherapy. ClinicalTrials.gov ID, NCT03782207.
02:43 PM
Duration 10mins Room B
IMpower010: ctDNA status in patients (pts) with NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)
E. Felip, M. K. Srivastava, M. Reck, H. Wakelee, N. Altorki, E. Vallieres, R. Liersch, M. Harada, H. Tanaka, J. T. Hamm, S. McCune, E. Bennett, B. Gitlitz, V. McNally, S. Novella, M. Ballinger, W. Zou, B. Y. Nabet, M. Das Thakur, C. Zhou

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:00 AM
Duration 5mins Room C
IMscin001 (Part 2: Randomized Phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Burotto M, Zvirbule Z, Mochalova A, Runglodvatana Y, Herraez-Baranda L, Liu S, Chan P, Shearer-Kang E, Shivhare M, Tosti N, Zanghi J, Leutgeb B, Felip E

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar